Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

OBJECTIVES: This study evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) as the first-line treatment following conventional synthetic DMARDs, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Dimitrios A, St John, Gregory, Etzel, Carol J, Fiore, Stefano, Blachley, Taylor, Kimura, Toshio, Punekar, Rajeshwari, Emeanuru, Kelechi, Choi, Jeannie, Boklage, Susan, Kremer, Joel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Recommendation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788059/
https://www.ncbi.nlm.nih.gov/pubmed/32719038
http://dx.doi.org/10.1136/annrheumdis-2020-217209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788059/
https://www.ncbi.nlm.nih.gov/pubmed/32719038
http://dx.doi.org/10.1136/annrheumdis-2020-217209

Ejemplares similares